NICE - Endorsed Technology Appraisals 2024/2025

Topics:

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2024/2025

The following technology appraisals have been endorsed during 2024/25. Information on technology appraisals endorsed in previous years can be found on the homepage. 

April 2024

TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Note this guidance updates and replaces NICE Technology Appraisal TA598, endorsed by the DoH in September 2019.

TA959 - Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over

TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

TA955 - Dupilumab for treating moderate to severe prurigo nodularis

TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema

‘Note this guidance updates and replaces NICE Technology Appraisals TA613, endorsed by the DoH in December 2019 and TA301, endorsed by the DoH in December 2013.’

Related articles

Back to top